PCN99 THE COST-EFFECTIVENESS AND BUDGET IMPACT ANALYSIS OF RITUXIMAB(HANLIKANG) FOR PATIENTS WITH DIFFUSE LARGE B-CELL LYMPHOMA IN CHINA
Abstract
Authors
M.M. Zhao Y. Xiang W. Juying S.H. Jia B.B. Chen C.S. Fan
M.M. Zhao Y. Xiang W. Juying S.H. Jia B.B. Chen C.S. Fan
ISPOR recommends that you update your browser for more security, speed and the best experience on ispor.org. Update my browser now